Kevin Hern | VP IR |
Dave Ricks | Chairman & CEO |
Josh Smiley | CFO |
Dan Skovronsky | President, Lilly Research Laboratories |
Enrique Conterno | President, Lilly Diabetes & Lilly U.S.A |
Patrik Jonsson | President of Lilly Bio Medicines |
Chris Schott | JPMorgan |
Umer Raffat | Evercore |
Terence Flynn | Goldman Sachs |
Tim Anderson | Wolfe Research |
Louise Chen | Cantor Fitzgerald |
Navin Jacob | UBS |
Seamus Fernandez | Guggenheim |
David Risinger | Morgan Stanley |
Steve Scala | Cowen |
Andrew Baum | Citi |
Ladies and gentlemen, thank you for standing by. Welcome to the Eli Lilly Q3 2019 Earnings Call. At this time all participant lines are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being recorded. I'd now like to turn the conference over to the Vice President of Investor Relations.